Skip to content
GERICLINICS

GeriQBank · Paper III · Q2

Isolated systolic hypertension and its management

High YieldAsked ×27-mark note
Topic
Cardiovascular Medicine
Chapter
Cardiovascular System & Thromboembolism
Years asked
Not recorded in the source
Frequency
Set 2× in Paper III (2009–2025)

As set in the university paper

  • Isolated systolic hypertension and its management.

    Paper III · Cardiovascular Medicine · asked ×2 · 7-mark note · see in paper list

Answer framework

  1. Definition — systolic ≥140 with diastolic <90; the dominant pattern in old age
  2. Pathophysiology — large-artery stiffness; loss of Windkessel function; early wave reflection; the therapeutic paradox
  3. Clinical significance — target-organ risks; pulse pressure; the diastolic J-curve
  4. Evaluation — out-of-office confirmation; white-coat effect, pseudohypertension, orthostatic drop; target-organ damage; secondary causes
  5. Management — lifestyle; first-line drugs and landmark trials; the second agent; titration against standing and diastolic pressure
  6. Recent updates — AHA/ACC 2025, ESPRIT, STEP, ESC 2024 frailty relaxation, anti-stiffness strategies and renal denervation

An exam answer plan drawn from the detailed answer below. Use it to attempt the question first.

Detailed answer

Pro · free in beta
Attempt it firstOutline your answer as a 7-mark note before revealing it — definition, causes, evaluation, management and the geriatric angle.Reveal answer

Short revision answer

  • Isolated systolic hypertension (ISH) is a systolic BP ≥140 mmHg with diastolic <90 mmHg, and a wide pulse pressure is its hallmark. It is the dominant pattern in old age — fewer than 20% of hypertensive people over 60 have a raised diastolic pressure.
  • It is caused by large-artery stiffness (elastin fragmentation, collagen cross-linking, medial calcification, reduced nitric oxide), not by raised peripheral resistance. Early return of the reflected wave in systole raises systolic and lowers diastolic pressure. Current drugs act on resistance rather than stiffness, so ISH is hard to control.
  • ISH independently raises the risk of stroke, coronary events, heart failure, AF, CKD and cognitive decline; pulse pressure predicts risk best in the very old. A treated diastolic below 60–65 mmHg risks myocardial ischaemia (the J-curve).
  • Confirm with repeated and out-of-office readings; exclude white-coat effect and pseudohypertension (Osler manoeuvre); check standing BP. Assess LVH, albuminuria, eGFR, fundi, lipids and glucose, and exclude renovascular disease, hyperaldosteronism, hyperparathyroidism and CKD.
  • Lifestyle: less salt, a DASH-type diet, potassium-rich foods, aerobic exercise, weight control and stopping smoking.
  • First-line drugs: a thiazide-like diuretic (chlorthalidone, indapamide) or a dihydropyridine CCB (amlodipine). Key trials: SHEP (stroke down 36%), Syst-Eur (down 42%), HYVET (over-80s) and the LIFE ISH substudy. Add an ACE inhibitor or ARB, preferring low-dose combinations; avoid beta blockers without a compelling indication.
  • Titrate against the standing BP and the diastolic pressure, and reduce treatment if there is symptomatic postural hypotension, falls or a diastolic below about 60 mmHg.
  • AHA/ACC 2025: a systolic goal of <130 mmHg (encouraging <120), individualised for frailty and limited life expectancy. ESPRIT (2024) and STEP support tighter control in fit older adults. ESC 2024 relaxes targets at age 85 and over, with orthostatic hypotension, or with frailty.
  • No drug yet targets arterial stiffness; renal denervation is a Class 2b option for resistant hypertension. A pulse pressure above 60–65 mmHg and a pulse wave velocity above 10 m/s mark arterial stiffening.

Condensed by GeriClinics from the detailed answer below, with no new facts added.

15-MARK ANSWER | 17 POINTS | RECURRING TOPIC

Definition

1.

Isolated systolic hypertension (ISH) = systolic BP ≥140 mmHg with diastolic BP <90 mmHg. Widened pulse pressure is the hallmark.

2.

It is the dominant pattern of hypertension in old age. NHANES III showed that fewer than 20% of hypertensive people over 60 have a raised diastolic pressure, and this proportion falls further with advancing age.

Pathophysiology — the core examination point

3.

ISH is caused by large-artery stiffness, not by raised peripheral resistance (which is the mechanism in the young).

4.

Mechanism: fragmentation of elastin, increased collagen cross-linking, calcification of the media, and endothelial dysfunction with reduced nitric oxide → loss of aortic Windkessel function.

5.

Consequence: the aorta cannot buffer stroke volume, so systolic pressure rises; the pulse wave travels faster and the reflected wave returns in systole instead of diastole, further augmenting systolic pressure and lowering diastolic pressure — hence the wide pulse pressure and reduced coronary perfusion pressure.

6.

Pathy's highlights the therapeutic paradox: current antihypertensives act mainly by reducing peripheral vascular resistance and have little effect on arterial stiffness, which is why ISH is difficult to control and why drugs targeting stiffness are an unmet need.

Clinical Significance

7.

ISH is a major independent risk factor for stroke, coronary events, heart failure, atrial fibrillation, chronic kidney disease progression and cognitive decline.

8.

Wide pulse pressure predicts risk better than systolic pressure alone in the very old.

9.

Low diastolic pressure (<60–65 mmHg) during treatment is a warning sign — coronary filling occurs in diastole, so excessive diastolic fall may precipitate myocardial ischaemia (the "J-curve").

Evaluation

10.

Confirm with repeated and out-of-office readings; exclude white-coat effect and pseudo-hypertension; check orthostatic drop (postural hypotension was present in a substantial proportion of the SHEP cohort at baseline).

11.

Assess target-organ damage: ECG/echocardiography for LV hypertrophy, urine albumin–creatinine ratio, creatinine/eGFR, fundoscopy, lipids and glucose.

12.

Exclude secondary causes relevant to old age listed in Essentials: atherosclerotic renovascular disease, primary hyperaldosteronism, hyperparathyroidism, chronic kidney disease and oestrogen therapy.

Management

13.

Non-pharmacological: sodium restriction, DASH-type diet, potassium-rich foods, aerobic exercise, weight optimisation, smoking cessation.

14.

First-line drugs: thiazide-like diuretics (chlorthalidone/indapamide) and dihydropyridine calcium channel blockers (amlodipine). These are the classes proven in the landmark ISH trials.

15.

Landmark trials to quote: SHEP (chlorthalidone-based; 36% stroke reduction), Syst-Eur (nitrendipine-based; 42% stroke reduction), HYVET (indapamide ± perindopril in the over-80s), and the LIFE ISH substudy (losartan superior to atenolol in ISH with LV hypertrophy).

16.

Add an ACE inhibitor or ARB as second agent; use a low-dose two-drug combination rather than maximising a single drug. Avoid beta blockers unless there is a compelling indication.

17.

Titrate to the systolic target while watching the diastolic pressure and the standing pressure. Reduce or stop treatment if the patient develops symptomatic postural hypotension, falls, or a diastolic pressure below about 60 mmHg.

Latest Updates (2023–Present)

2025 AHA/ACC guideline makes no separate ISH target: the systolic goal of <130 mmHg (with encouragement toward <120) applies, but individualisation is explicitly allowed for frailty, orthostatic hypotension and limited life expectancy. ESPRIT trial (Lancet 2024) — intensive systolic lowering to <120 mmHg reduced major vascular events versus <140 mmHg in high-risk adults, strengthening the case for tighter systolic control in fit older patients. STEP trial (NEJM 2021, widely cited in 2023–2025 guidance) — in adults aged 60–80, a target of 110–130 mmHg reduced cardiovascular events; a substantial proportion of participants had a predominantly systolic pattern. 2024 ESC guideline specifically advises that in patients aged ≥85, with orthostatic hypotension, or with moderate-to-severe frailty, the systolic target may be relaxed — the most explicit statement so far that ISH management is frailty-dependent.

Interest continues in anti-stiffness strategies (SGLT2 inhibitors, mineralocorticoid receptor antagonists, advanced glycation end-product cross-link breakers) and in renal denervation (Class 2b, 2025 ACC/AHA) for resistant systolic hypertension, but no drug is yet licensed specifically to reduce arterial stiffness.

Current Practice Update

Textbook position Current evidence (2023–2026)

Systolic goal <140 mmHg; caution that benefit Systolic goal <130 mmHg (ACC/AHA 2025) or 120–129 mmHg (ESC 2024) in patients who may not extend below 130 mmHg. tolerate it.

No drug targets arterial stiffness; new agents Still true — this remains an unmet need; renal denervation is the only new device-based "required". option (Class 2b).

Frailty-adjusted targets described as Frailty-adjusted relaxation of targets is now written into ESC 2024 and ACC/AHA 2025. unresolved.

Stepped care with single agents. Low-dose single-pill combination therapy is preferred first-line for most.

Extra Points to Remember (recurring topic)

Pulse pressure = SBP − DBP. A pulse pressure above 60–65 mmHg indicates significant arterial stiffening and independently predicts cardiovascular events in the elderly.

Pulse wave velocity (carotid–femoral) is the reference measure of arterial stiffness; >10 m/s indicates target-organ damage. Osler's manoeuvre — a palpable, pulseless radial artery when the cuff is inflated above systolic pressure — is the classic bedside clue to pseudo-hypertension.

CAFE study (Circulation 2006, cited in Pathy's): drugs differ in their effect on central aortic pressure even when brachial pressures are equal — amlodipine-based therapy lowered central pressure more than atenolol-based therapy. Mnemonic for first-line drugs in ISH: "CD" — Calcium channel blocker and Diuretic (thiazide-like). Remember the three ISH trial names in order of era: SHEP → Syst-Eur → HYVET → (now) STEP and ESPRIT.

Examiner's Tip

"Isolated systolic hypertension is a disease of large-artery stiffness, not of increased peripheral resistance." · "Loss of aortic elasticity causes early return of the reflected pulse wave in systole, raising systolic and lowering diastolic pressure, which widens the pulse pressure." · "Thiazide-like diuretics and dihydropyridine calcium channel blockers are first-line, supported by SHEP, Syst-Eur and HYVET." · "Treatment must be titrated against the standing blood pressure, and a diastolic pressure below 60 mmHg should prompt caution because coronary perfusion occurs in diastole."

How was your recall?

Rating marks the question complete. “Need another pass” also adds it to your bookmarks.

References

Spotted an error or something out of date?Report a problem with this page